L'intérêt à découvert pour Editas Medicine donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Editas Medicine. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Editas Medicine (NASDAQ:EDIT) Stock, Rapport sur les intérêts à découvert

Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Inc

BofA Securities downgraded Editas Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), citing few value-driving catalysts <a target="_blank" href="https://www.benzinga.com/quote/EDIT/analyst-ratings" rel="noreferrer noopener">in the near term</a>.
In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301).
The company is developing reni-cel for sickle cell disease and transfusion-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41710488/editas-medicine-announces-third-quarter-2024-results-and-business-updates" rel="noreferrer noopener">dependent Beta Thalassemia</a>.
The company is on track to share additional clinical and patient-reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology Annual Meeting in December.
The company has completed enrollment of the adult cohort of the EdiTHAL trial for thalassemia and continues patient dosing.
The analyst notes that Editas announced a shift in focus toward in vivo development, specifically working on lipid nanoparticle (LNP) formulations for treating sickle cell disease (SCD) and thalassemia.
While preclinical data shows some progress—29% editing in hematopoietic stem and progenitor cells (HSPCs) and around 20% of red blood cells expressing fetal hemoglobin (HbF)—more evidence is needed to prove functional benefits and advance to clinical trials.
Meanwhile, competitors like Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) and CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) are investing heavily in their in vivo programs for SCD and thalassemia, with better-prepared manufacturing and development for clinical trials.
Given the deprioritization of reni-cel and the increasingly competitive environment for ex vivo therapies, BofA has reduced estimates and probabilities of success in SCD and beta-thal to 10% (from 60% prior).
The analyst downgraded from Buy to Underperform, with a price target of $1, down from $13.
This intensifying competition, limited short-term clinical milestones, and declining interest in gene editing pose challenges for Editas and could pressure its stock in the near term.
Price Action: EDIT stock is down 0.41% at $2.43 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market" target="_blank" rel="noreferrer noopener">AMD Teams Up With Taiwan Semi To Take On Samsung In Smartphone Market</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Analyst Color

Biotech

Equities

News

Downgrades

Health Care

Price Target

Analyst Ratings

Trading Ideas

General

BEAM

CRSP

EDIT

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy and maintains $12 price target.

Chardan Capital Maintains Buy on Editas Medicine, Maintains $12 Price Target

RBC Capital analyst Luca Issi maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Sector Perform and lowers the price target from $8 to $5.

RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $5

Stifel analyst Dae Gon Ha maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy and lowers the price target from $17 to $11.

Stifel Maintains Buy on Editas Medicine, Lowers Price Target to $11

Truist Securities analyst Joon Lee maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy and lowers the price target from $12 to $8.

Truist Securities Maintains Buy on Editas Medicine, Lowers Price Target to $8

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Overweight and lowers the price target from $9 to $7.

Wells Fargo Maintains Overweight on Editas Medicine, Lowers Price Target to $7

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Equal-Weight and lowers the price target from $7 to $5.

Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $5

Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) reported quarterly losses of $(0.75) per share which met the analyst consensus estimate. This is a 36.36 percent decrease over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $61.00 thousand which missed the analyst consensus estimate of $2.25 million by 97.28 percent. This is a 98.86 percent decrease over sales of $5.34 million the same period last year.

Earnings

Earnings Misses

Editas Medicine Q3 EPS $(0.75), Inline, Sales $61.00K Miss $2.25M Estimate

Evercore ISI Group analyst Liisa Bayko maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a In-Line and lowers the price target from $7 to $3.

Evercore ISI Group Maintains In-Line on Editas Medicine, Lowers Price Target to $3

In the preceding three months, 7 analysts have released ratings for Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.86, a high estimate of $15.00, and a low estimate of $7.00. This current average represents a 32.84% decrease from the previous average price target of $16.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1729695670_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Editas Medicine's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Soumit Roy</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Editas Medicine. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Editas Medicine compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Editas Medicine's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Editas Medicine's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EDIT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Editas Medicine analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Editas Medicine</h2>
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
<h3>Breaking Down Editas Medicine's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Editas Medicine's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -82.23% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Editas Medicine's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -13178.75%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Editas Medicine's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -25.69% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -16.39%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts

Correction: Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Overweight and lowers the price target from $27 to $9. (Rating changed)

Correction: Wells Fargo Maintains Overweight on Editas Medicine, Lowers Price Target to $9. (Rating changed)

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Equal-Weight and lowers the price target from $27 to $9.

Wells Fargo Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $9

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy and lowers the price target from $20 to $12.

Chardan Capital Maintains Buy on Editas Medicine, Lowers Price Target to $12

The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP) formulation for extrahepatic tissue delivery.&nbsp;
In Vivo Proof of Concept Data Highlights
<ul>
<li>Achieved highly competitive level of in vivo hematopoietic stem and progenitor cell (HSPC) editing utilizing a novel, Editas-proprietary targeted lipid nanoparticle (t-LNP) for extrahepatic tissue delivery in a humanized mouse model, mice engrafted with human hematopoietic stem cells.</li>
<li>Enabled an editing level of 29% in HSPCs after a single dose by utilizing a hematopoietic stem cell targeting strategy and tLNP formulation optimization.</li>
<li>Further demonstrated that editing with the Company's proprietary tLNP formulation resulted in the functional outcome of HbF induction, indicated by the presence of HbF expressing human red blood cells (on average 20%) that populate in the host by one month.&nbsp;</li>
<li>This level of in vivo editing in a humanized mouse model after a single dose constitutes a highly competitive dataset relative to data in the public domain for the development of an in vivo medicine for sickle cell disease and beta thalassemia.</li>
</ul>
The Company is also providing business development and financial updates, including that it initiated a process to partner or out-license reni-cel.

Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells

Editas Medicine And Genevant Sciences Enter Nonexclusive License Agreement To Combine  Editas Medicine's CRISPR Cas12a Genome Editing Systems With Genevant's LNP Technology In The Development Of In Vivo Gene Editing Medicines Directed To Two Undisclosed Targets In Editas' Upregulation Strategy

The upfront cash payment brings non-dilutive capital to Editas Medicine, helping enable further pipeline development and related strategic priorities.
Under the terms of the agreement, Editas Medicine will receive an upfront cash payment of&nbsp;$57 million&nbsp;in exchange for up to&nbsp;100%&nbsp;of certain future annual license fees payable to Editas Medicine, ranging from&nbsp;$5 million&nbsp;to&nbsp;$40 million&nbsp;per year (inclusive of certain sales-based annual license fees that may become due) and a mid-double-digit percentage of Editas Medicine&#39;s portion of a&nbsp;$50 million&nbsp;contingent upfront payment for which Editas Medicine is eligible under the Vertex license agreement.
In addition to a portion of any such contingent upfront payment, Editas Medicine retains rights to fixed annual license fees for 2024 and a mid-single-digit million-dollar payment due to Editas Medicine in the event of Vertex&#39;s achievement of certain annual sales milestones.

Asset Sales

Editas Medicine Reports Sale Of Certain Future License Fees, Other Payments Owed Under Cas9 License Agreement With Vertex To DRI Healthcare Trust Subsidiary For Upfront Cash Payment Of $57M

RBC Capital analyst Luca Issi reiterates Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Sector Perform and maintains $8 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Editas Medicine, Maintains $8 Price Target

Throughout the last three months, 4 analysts have evaluated Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Editas Medicine and provided 12-month price targets. The average target is $11.75, accompanied by a high estimate of $15.00 and a low estimate of $7.00. Experiencing a 16.07% decline, the current average is now lower than the previous average price target of $14.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726606841_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Editas Medicine by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soumit Roy</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Editas Medicine. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Editas Medicine compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Editas Medicine's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Editas Medicine's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EDIT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Editas Medicine analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Editas Medicine</h2>
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
<h3>Understanding the Numbers: Editas Medicine's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Editas Medicine's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -82.23%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Editas Medicine's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -13178.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -25.69%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -16.39%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Editas Medicine's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Editas Medicine Stands With Analysts

Jones Trading analyst Soumit Roy initiates coverage on Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy rating and announces Price Target of $13.

Initiation

Jones Trading Initiates Coverage On Editas Medicine with Buy Rating, Announces Price Target of $13

Editas Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter.
Collaboration and other research and development (R&amp;D) revenues, which comprise the company&#39;s top line, were $0.5 million in the second quarter, down from $2.9 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. The year-over-year decline in revenues can be attributed to reduced drug supply activity with collaborators.
Shares of Editas were down 12.2% on Aug 7 following the announcement of the results.
<h3>Quarter in Detail</h3>
In the second quarter of 2024, R&amp;D expenses increased 82% to $54.2 million compared with $29.8 million reported in the year-ago period. The massive uptick in R&amp;D expenses can be attributed to higher&nbsp;clinical and manufacturing costs related to the accelerated progression of Editas&#39; reni-cel program as well as costs attributable to&nbsp;other&nbsp;research activities.
General and administrative expenses were $18.2 million in the reported quarter, up 6% year over year, due to higher intellectual property and patent-related fees due to increased legal activity.
Editas had cash, cash equivalents and investments worth $318.3&nbsp;million as of Jun&nbsp;30, 2024, down from $376.8 million recorded as of Mar 31, 2024. The company expects its existing cash, cash equivalents and marketable securities, together with the near-term annual license fees and the contingent upfront payment from&nbsp;Vertex Pharmaceuticals&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>), to fund operating expenses and capital expenditure in 2026.
In late 2023, Vertex&nbsp;in-licensed&nbsp;rights to Editas&#39; Cas9 gene editing tool to develop its newly approved sickle cell disease gene therapy, Casgevy.
Shares of Editas have plunged 59.4% year to date compared with the&nbsp;industry&#39;s decline of 4.4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/06/73699.jpg?v=2014758018" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h3>Pipeline Updates</h3>
Editas has no approved products in its portfolio at the moment. Therefore, pipeline development remains the key focus of the company.
The company is evaluating the safety and efficacy of its investigational gene-editing medicine, reni-cel (renizgamglogene autogedtemcel, previously EDIT-301), in phase I/II/III RUBY study for treating SCD.
EDIT has completed enrollment and continues to dose SCD patients in the adult cohort of the RUBY study. The company has completed enrollment in the adolescent cohort of the RUBY study. Editas remains on track to report substantive data from the RUBY study by the end of 2024.
The company is also evaluating reni-cel for the treatment of transfusion-dependent beta thalassemia (TDT). Editas has completed enrollment in the adult cohort and continues to dose patients in the EdiTHAL study for TDT. The company is also on track to report additional clinical data from the EdiTHAL study by the end of 2024.
Please note that during the reported quarter, Editas reported&nbsp;new positive data from the RUBY study of reni-cel in 18 patients with SCD and the EdiTHAL study of the same in seven patients with TDT. In the expected data readout from the RUBY and EdiTHAL studies by year-end, EDIT will provide additional efficacy data.
<div class="chart_embed">
<h3>Editas Medicine, Inc. Price and Consensus</h3>
<img alt="Editas Medicine, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/d5/1723118191.png" style="height:310px; width:600px" title="" />
Editas Medicine, Inc. price-consensus-chart | Editas Medicine, Inc. Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Editas currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Annovis Bio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anvs#NYSE">ANVS</a>) and&nbsp;Akero Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>), each carrying a Zacks Rank #2 (Buy) at present.
In the past 60 days, the Zacks Consensus Estimate for Annovis&#39; 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $1.95 to $1.91. Year to date, shares of ANVS have plunged 57.1%.
ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.
In the past 60 days, estimates for Akero Therapeutics&#39; 2024 loss per share have narrowed from $3.87 to $3.82. During the same period, loss per share estimates for 2025 have remained constant at $4.29. Year to date, shares of AKRO have gained 1.4%.
Akero&#39;s earnings beat estimates in one of the trailing four quarters, missed twice and matched once, delivering an average negative surprise of 5.10%.
<a href="https://www.zacks.com/stock/news/2319312/editas-edit-q2-earnings-revenues-miss-estimates-stock-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-2319312">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

Markets

AKRO

ANVS

VRTX

Editas Q2 Earnings & Revenues Miss Estimates, Stock Down

Editas Medicine upgraded at Evercore on CRISPR platform

Warning: EDIT is at high risk of performing badly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Rige...

Biotech Alert: Searches spiking for these stocks today

CRISPR, Beam, other gene editing names up significantly

Catalyst Watch: Nvidia earnings, Microsoft Ignite, crypto confidence, and P&G event

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Editas Medicine (EDIT – Research Report) received a Sell rating and price target from Bank of America Securities analyst Alec Stranahan on November...

Bank of America Securities downgrades Editas Medicine (EDIT) to a Sell

Editas cut to underperform by BofA, price objective slashed to $1

ABIT

ASAN

BIDU

BILL

BKKT

BRBR

BRPHF

BTBT

CRNC

CRWS

FCEL

FTNT

FWONA

GEHC

HNST

HYMTF

INOD

INTU

IONS

JACK

JAKK

MARA

MNDY

MRUS

MSTR

MVIS

NAPA

NVDA

ORCL

PANW

PCOR

PRME

PYCR

QGEN

QUAD

RIGL

RIOT

ROST

RVNC

RVTY

SAVE

SNOW

STLA

STNG

TCOM

TRMD

USPH

VERV

VLKAF

XPEV

Press Releases

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Editas Medicine to Participate in Upcoming Investor Conferences

Financing

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Comments

Editas Medicine

Intérêt court

Editas Medicine (NASDAQ:EDIT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL